Nanoparticle-Mediated Mitochondrial Damage Induces Apoptosis in Cancer

ACS Applied Materials and Interfaces

Volumn 8, Issue 21, 2016, Pages 13218-13231

  Mallick, Abhik ^a   More, Piyush ^a   Syed, Muhammed Muazzam Kamil ^a   Basu, Sudipta ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

cancer; mitochondria; nanoparticle; obatoclax; tocopheryl succinate

Indexed keywords

CELL DEATH; CHEMOTHERAPY; CYTOLOGY; DISEASES; DRUG THERAPY; ELECTRON TRANSPORT PROPERTIES; NANOPARTICLES;

CANCER; CANCER THERAPEUTICS; ELECTRON TRANSPORT CHAIN; MITOCHONDRIAL DAMAGE; OBATOCLAX; SPHERICAL NANOPARTICLES; TRIPHENYLPHOSPHINES; TRIPLE-NEGATIVE BREAST CANCERS;

MITOCHONDRIA;

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE; OBATOCLAX; ORGANOPHOSPHORUS COMPOUND; PYRROLE DERIVATIVE; TRIPHENYLPHOSPHINE;

APOPTOSIS; CHEMISTRY; DRUG EFFECT; HELA CELL LINE; HUMAN; MITOCHONDRION; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG CARRIERS; HELA CELLS; HUMANS; MITOCHONDRIA; NANOPARTICLES; ORGANOPHOSPHORUS COMPOUNDS; PYRROLES;

EID: 84973386982     PISSN: 19448244     EISSN: 19448252     Source Type: Journal    
DOI: 10.1021/acsami.6b00263     Document Type: Article

References (63)

1. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 2010, 127, 2893-2917 10.1002/ijc.25516
2. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer Statistics, 2014 Ca-Cancer J. Clin. 2014, 64, 9-29 10.3322/caac.21208
3. DeVita, V. T., Jr.; Chu, E. A History of Cancer Chemotherapy Cancer Res. 2008, 68, 8643-8653 10.1158/0008-5472.CAN-07-6611
4. Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer Drug Resistance: an Evolving Paradigm Nat. Rev. Cancer 2013, 13, 714-726 10.1038/nrc3599
5. Bedard, P. L.; Hansen, A. R.; Ratain, M. J.; Siu, L. L. Tumour Heterogeneity in the Clinic Nature 2013, 501, 355-364 10.1038/nature12627
6. Junttila, M. R.; de Sauvage, F. J. Influence of Tumour Micro-Environment Heterogeneity on Therapeutic Response Nature 2013, 501, 346-354 10.1038/nature12626
7. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting Mitochondria for Cancer Therapy Nat. Rev. Drug Discovery 2010, 9, 447-464 10.1038/nrd3137
8. Galluzzi, L.; Kepp, O.; Kroemer, G. Mitochondria: Master Regulators of Danger Signalling Nat. Rev. Mol. Cell Biol. 2012, 13, 780-788 10.1038/nrm3479
9. Weinberg, S. E.; Chandel, N. S. Targeting Mitochondria Metabolism for Cancer Therapy Nat. Chem. Biol. 2014, 11, 9-15 10.1038/nchembio.1712
10. Nunnari, J.; Suomalainen, A. Mitochondria: in Sickness and in Health Cell 2012, 148, 1145-1159 10.1016/j.cell.2012.02.035
11. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges Nat. Rev. Cancer 2005, 5, 161-171 10.1038/nrc1566
12. Kim, B. Y.; Rutka, J. T.; Chan, W. C. Nanomedicine N. Engl. J. Med. 2010, 363, 2434-2443 10.1056/NEJMra0912273
13. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760 10.1038/nnano.2007.387
14. Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery Materials for siRNA Therapeutics Nat. Mater. 2013, 12, 967-977 10.1038/nmat3765
15. Mitragotri, S.; Burke, P. A.; Langer, R. Overcoming the Challenges in Administering Biopharmaceuticals: Formulation and Delivery Strategies Nat. Rev. Drug Discovery 2014, 13, 655-672 10.1038/nrd4363
16. Marrache, S.; Pathak, R. K.; Dhar, S. Detouring of Cisplatin to Access Mitochondrial Genome for Overcoming Resistance Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 10444-10449 10.1073/pnas.1405244111
17. Marrache, S.; Dhar, S. The Energy Blocker inside the Power House: Mitochondria Targeted Delivery of 3-Bromopyruvate Chem. Sci. 2015, 6, 1832-1845 10.1039/C4SC01963F
18. Smith, R. A.; Porteous, C. M.; Gane, A. M.; Murphy, M. P. Delivery of Bioactive Molecules to Mitochondria In Vivo Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 5407-5412 10.1073/pnas.0931245100
19. Marrache, S.; Dhar, S. Engineering of Blended Nanoparticle Platform for Delivery of Mitochondria-Acting Therapeutics Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 16288-16293 10.1073/pnas.1210096109
20. Zhou, J.; Zhao, W. Y.; Ma, X.; Ju, R. J.; Li, X. Y.; Li, N.; Sun, M. G.; Shi, J. F.; Zhang, C. X.; Lu, W. L. The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugate in Resistant Lung Cancer Biomaterials 2013, 34, 3626-3638 10.1016/j.biomaterials.2013.01.078
21. Qu, Q.; Ma, X.; Zhao, Y. Targeted Delivery of Doxorubicin to Mitochondria Using Mesoporous Silica Nanoparticle Nanocarriers Nanoscale 2015, 7, 16677-16686 10.1039/C5NR05139H
22. Wisnovsky, S. P.; Wilson, J. J.; Radford, R. J.; Pereira, M. P.; Chan, M. R.; Laposa, R. R.; Lippard, S. J.; Kelley, S. O. Targeting Mitochondrial DNA with a Platinum-Based Anticancer Agent Chem. Biol. 2013, 20, 1323-1328 10.1016/j.chembiol.2013.08.010
23. Fonseca, S. B.; Pereira, M. P.; Mourtada, R.; Gronda, M.; Horton, K. L.; Hurren, R.; Minden, M. D.; Schimmer, A. D.; Kelley, S. O. Rerouting Chlorambucil to Mitochondria Combats Drug Deactivation and Resistance in Cancer Cells Chem. Biol. 2011, 18, 445-453 10.1016/j.chembiol.2011.02.010
24. Chamberlain, G. R.; Tulumello, D. V.; Kelley, S. O. Targeted Delivery of Doxorubicin to Mitochondria ACS Chem. Biol. 2013, 8, 1389-1395 10.1021/cb400095v
25. Mallick, A.; More, P.; Ghosh, S.; Chippalkatti, R.; Chopade, B. A.; Lahiri, M.; Basu, S. Dual Drug Conjugated Nanoparticle for Simultaneous Targeting of Mitochondria and Nucleus in Cancer Cells ACS Appl. Mater. Interfaces 2015, 7, 7584-7598 10.1021/am5090226
26. Yoong, S. L.; Wong, B. S.; Zhou, Q. L.; Chin, C. F.; Li, J.; Venkatesan, T.; Ho, H. K.; Yu, V.; Ang, W. H.; Pastorin, G. Enhanced Cytotoxicity to Cancer Cells by Mitochondria-Targeting MWCNTs Containing Platinum(IV) Prodrug of Cisplatin Biomaterials 2014, 35, 748-759 10.1016/j.biomaterials.2013.09.036
27. Song, Y. F.; Liu, D. Z.; Cheng, Y.; Liu, M.; Ye, W. L.; Zhang, B. L.; Liu, X. Y.; Zhou, S. Y. Dual Subcellular Compartment Delivery of Doxorubicin to Overcome Drug Resistant and Enhance Antitumor Activity Sci. Rep. 2015, 5, 16125 10.1038/srep16125
28. Feldhaeusser, B.; Platt, S. R.; Marrache, S.; Kolishetti, N.; Pathak, R. K.; Montgomery, D. J.; Reno, L. R.; Howerth, E.; Dhar, S. Evaluation of Nanoparticle Delivered Cisplatin in Beagles Nanoscale 2015, 7, 13822-13830 10.1039/C5NR03447G
29. Kalathil, A. A.; Kumar, A.; Banik, B.; Ruiter, T. A.; Pathak, R. K.; Dhar, S. New Formulation of Old Aspirin for Better Delivery Chem. Commun. 2016, 52, 140-143 10.1039/C5CC07316B
30. Kazak, L.; Reyes, A.; Holt, I. J. Minimizing the Damage: Repair Pathways Keep Mitochondrial DNA Intact Nat. Rev. Mol. Cell Biol. 2012, 13, 659-671 10.1038/nrm3439
31. Yu, C.; Zhou, M.; Zhang, X.; Wei, W.; Chen, X.; Zhang, X. Smart Doxorubicin Nanoparticles with High Drug Payload for Enhanced Chemotherapy against Drug Resistance and Cancer Diagnosis Nanoscale 2015, 7, 5683-5690 10.1039/C5NR00290G
32. Jin, R.; Ji, X.; Yang, Y.; Wang, H.; Cao, A. Self-Assembled Graphene-Dextran Nanohybrid for Killing Drug-Resistant Cancer Cells ACS Appl. Mater. Interfaces 2013, 5, 7181-7189 10.1021/am401523y
33. Wang, Y. C.; Wang, F.; Sun, T. M.; Wang, J. Redox-Responsive Nanoparticles from the Single Disulfide Bond-Bridged Block Copolymer as Drug Carriers for Overcoming Multidrug Resistance in Cancer Cells Bioconjugate Chem. 2011, 22, 1939-1945 10.1021/bc200139n
34. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial Drug Therapy for Cancer in the Post-Genomic Era Nat. Biotechnol. 2012, 30, 679-692 10.1038/nbt.2284
35. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal Targeting of Tumour Cells and Neovasculature with a Nanoscale Delivery System Nature 2005, 436, 568-572 10.1038/nature03794
36. Zhao, Y.; Chen, F.; Pan, Y.; Li, Z.; Xue, X.; Okeke, C. I.; Wang, Y.; Li, C.; Peng, L.; Wang, P. C.; Ma, X.; Liang, X. J. Nanodrug Formed by Coassembly of Dual Anticancer Drugs To Inhibit Cancer Cell Drug Resistance ACS Appl. Mater. Interfaces 2015, 7, 19295-19305 10.1021/acsami.5b05347
37. Hu, S. H.; Chen, S. Y.; Gao, X. Multifunctional Nanocapsules for Simultaneous Encapsulation of Hydrophilic and Hydrophobic Compounds and On-Demand Release ACS Nano 2012, 6, 2558-2565 10.1021/nn205023w
38. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the Cancer Kinome Through Polypharmacology Nat. Rev. Cancer 2010, 10, 130-137 10.1038/nrc2787
39. Dong, L. F.; Low, P.; Dyason, J. C.; Wang, X. F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J. Alpha-Tocopheryl Succinate Induces Apoptosis by Targeting Ubiquinone-Binding Sites in Mitochondrial Respiratory Complex II Oncogene 2008, 27, 4324-4335 10.1038/onc.2008.69
40. Dong, L. F.; Freeman, R.; Liu, J.; Zobalova, R.; Marin-Hernandez, A.; Stantic, M.; Rohlena, J.; Valis, K.; Rodriguez-Enriquez, S.; Butcher, B.; Goodwin, J.; Brunk, U. T.; Witting, P. K.; Moreno-Sanchez, R.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J. Suppression of Tumor Growth In Vivo by the Mitocan Alpha-Tocopheryl Succinate Requires Respiratory Complex II Clin. Cancer Res. 2009, 15, 1593-1600 10.1158/1078-0432.CCR-08-2439
41. Kruspig, B.; Zhivotovsky, B.; Gogvadze, V. Contrasting Effects of α-Tocopheryl Succinate on Cisplatin- and Etoposide-Induced Apoptosis Mitochondrion 2013, 13, 533-538 10.1016/j.mito.2012.08.001
42. Zhang, X.; Peng, X.; Yu, W.; Hou, S.; Zhao, Y.; Zhang, Z.; Huang, X.; Wu, K. Alpha Tocopheryl Succinate Enhances Doxorubicin-Induced Apoptosis in Human Gastric Cancer Cell via Promotion of Doxorubicin Influx and Suppression of Doxorubicin Efflux Cancer Lett. 2011, 307, 174-181 10.1016/j.canlet.2011.04.001
43. Kanai, K.; Kikuchi, E.; Mikami, S.; Suzuki, E.; Uchida, Y.; Kodaira, K.; Miyajima, A.; Ohigashi, T.; Nakashima, J.; Oya, M. Vitamin E Succinate Induced Apoptosis and Enhanced Chemosensitivity to Paclitaxel in Human Bladder Cancer Cells In Vitro and In Vivo Cancer Sci. 2010, 101, 216-223 10.1111/j.1349-7006.2009.01362.x
44. Maryanoff, B. E.; Reitz, A. B.; Duhl-Emswiler, B. A. Stereochemistry of the Wittig reaction. Effect of Nucleophilic Groups in the Phosphonium Ylide J. Am. Chem. Soc. 1985, 107, 217-226 10.1021/ja00287a040
45. Sengupta, P.; Basu, S.; Soni, S.; Pandey, A.; Roy, B.; Oh, M. S.; Chin, K. T.; Paraskar, A. S.; Sarangi, S.; Connor, Y.; Sabbisetti, V. S.; Kopparam, J.; Kulkarni, A.; Muto, K.; Amarasiriwardena, C.; Jayawardene, I.; Lupoli, N.; Dinulescu, D. M.; Bonventre, J. V.; Mashelkar, R. A.; Sengupta, S. Cholesterol-Tethered Platinum II-Based Supramolecular Nanoparticle Increases Antitumor Efficacy and Reduces Nephrotoxicity Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 11294-11299 10.1073/pnas.1203129109
46. Schimmer, A. D.; OBrien, S.; Kantarjian, H.; Brandwein, J.; Cheson, B. D.; Minden, M. D.; Yee, K.; Ravandi, F.; Giles, F.; Schuh, A.; Gupta, V.; Andreeff, M.; Koller, C.; Chang, H.; Kamel-Reid, S.; Berger, M.; Viallet, J.; Borthakur, G. A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies Clin. Cancer Res. 2008, 14, 8295-8301 10.1158/1078-0432.CCR-08-0999
47. OBrien, S. M.; Claxton, D. F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M. J.; Viallet, J.; Cheson, B. D. Phase I Study of Obatoclax Mesylate (GX15-070), a Small Molecule Pan-Bcl-2 Family Antagonist, in Patients with Advanced Chronic Lymphocytic Leukemia Blood 2008, 113, 299-305 10.1182/blood-2008-02-137943
48. Paik, P. K.; Rudin, C. M.; Brown, A.; Rizvi, N. A.; Takebe, N.; Travis, W.; James, L.; Ginsberg, M. S.; Juergens, R.; Markus, S.; Tyson, L.; Subzwari, S.; Kris, M. G.; Krug, L. M. A Phase I Study of Obatoclax Mesylate, a Bcl-2 Antagonist, Plus Topotecan in Solid Tumor Malignancies Cancer Chemother. Pharmacol. 2010, 66, 1079-1085 10.1007/s00280-010-1265-5
49. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S. R.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C. Small Molecule Obatoclax (GX15-070) Antagonizes MCL-1 and Overcomes MCL-1-Mediated Resistance to Apoptosis Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19512-19517 10.1073/pnas.0709443104
50. Harris, J. M.; Chess, R. B. Effect of Pegylation on Pharmaceuticals Nat. Rev. Drug Discovery 2003, 2, 214-221 10.1038/nrd1033
51. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs Cancer Res. 1986, 46, 6387-6392
52. Wang, J.; Mao, W.; Lock, L. L.; Tang, J.; Sui, M.; Sun, W.; Cui, H.; Xu, D.; Shen, Y. The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment ACS Nano 2015, 9, 7195-7206 10.1021/acsnano.5b02017
53. Champion, J. A.; Mitragotri, S. Role of Target Geometry in Phagocytosis Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 4930-4934 10.1073/pnas.0600997103
54. Wang, L.; Liu, Y.; Li, W.; Jiang, X.; Ji, Y.; Wu, X.; Xu, L.; Qiu, Y.; Zhao, K.; Wei, T.; Li, Y.; Zhao, Y.; Chen, C. Selective Targeting of Gold Nanorods at the Mitochondria of Cancer Cells: Implications for Cancer Therapy Nano Lett. 2011, 11, 772-780 10.1021/nl103992v
55. Doherty, G. J.; McMahon, H. T. Mechanisms of Endocytosis Annu. Rev. Biochem. 2009, 78, 857-902 10.1146/annurev.biochem.78.081307.110540
56. Boya, P.; Kroemer, G. Lysosomal Membrane Permeabilization in Cell Death Oncogene 2008, 27, 6434-6451 10.1038/onc.2008.310
57. Rin Jean, S.; Tulumello, D. V.; Wisnovsky, S. P.; Lei, E. K.; Pereira, M. P.; Kelley, S. O. Molecular Vehicles for Mitochondrial Chemical Biology and Drug Delivery ACS Chem. Biol. 2014, 9, 323-333 10.1021/cb400821p
58. Pathak, R. K.; Marrache, S.; Harn, D. A.; Dhar, S. Mito-DCA: A Mitochondria Targeted Molecular Scaffold for Efficacious Delivery of Metabolic Modulator Dichloroacetate ACS Chem. Biol. 2014, 9, 1178-1187 10.1021/cb400944y
59. Petronilli, V.; Miotto, G.; Canton, M.; Brini, M.; Colonna, R.; Bernardi, P.; Di Lisa, F. Transient and Long-Lasting Openings of the Mitochondrial Permeability Transition Pore can be Monitored Directly in Intact Cells by Changes in Mitochondrial Calcein Fluorescence Biophys. J. 1999, 76, 725-734 10.1016/S0006-3495(99)77239-5
60. Tait, S. W.; Green, D. R. Mitochondria and Cell Death: Outer Membrane Permeabilization and Beyond Nat. Rev. Mol. Cell Biol. 2010, 11, 621-632 10.1038/nrm2952
61. Marinio, G.; Niso-Santano, M.; Baehrecke, E. H.; Kroemer, G. Self-Consumption: The Interplay of Autophagy and Apoptosis Nat. Rev. Mol. Cell Biol. 2014, 15, 81-94 10.1038/nrm3735
62. Samali, A.; Cai, J.; Zhivotovsky, B.; Jones, D. P.; Orrenius, S. Presence of a Pre-Apoptotic Complex of Pro-Caspase-3, Hsp60 and Hsp10 in the Mitochondrial Fraction of Jurkat Cells EMBO J. 1999, 18, 2040-2048 10.1093/emboj/18.8.2040
63. Akao, Y.; Otsuki, Y.; Kataoka, S.; Ito, Y.; Tsujimoto, Y. Multiple Subcellular Localization of bcl-2: Detection in Nuclear Outer Membrane, Endoplasmic Reticulum Membrane, and Mitochondrial Membranes Cancer Res. 1994, 54, 2468-2471